Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience

References

• Canellos GP, Anderson JR, Propert KJ, et al Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386–2395.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630–637.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:2835–2841.
   PubMed Web of Science ®Google Scholar
• Bonfante V, Santoro A, Viviani S, et al Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997;15:528–534.
   PubMed Web of Science ®Google Scholar
• Longo DL, Duffey PL, Young RC, et al Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210–218.
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J, Sieber M, Dhiel V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280–1286.
   PubMed Web of Science ®Google Scholar
• Bonfante V, Viviani S, Santoro A, et al Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998;103:533–535.
   PubMed Web of Science ®Google Scholar
• Santoro A, Magagnoli M, Spina M, et al Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92:35–41.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Taghipour G, Milligan D, et al High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997;20:745–752.
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Diviné M, et al Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002;20:467–475.
   PubMed Web of Science ®Google Scholar
• Tarella C, Zallio F, Caracciolo D, et al High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia 2001;15:256–263.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Weisdorf DJ, Defor TE, et al Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12:1065–1072.
   PubMed Web of Science ®Google Scholar
• Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol 2008;26:5240–5247.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powles R, et al Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1312–1319.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Viviani S, Bonfante V, Santoro A, et al Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 1999;5:275–282.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Siena S, Bregni M, et al Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991;2:645–653.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;34:187–220.
   Google Scholar
• Bierman PJ, Bagin RG, Jagannath S, et al High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993;4:767–773.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Forman SJ, et al The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529–539.
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Phillips GL, et al High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473–1478.
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Mapara M, et al Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116–123.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Rowlings PA, Zhang MJ, et al Autotransplant for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534–545.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Chao NJ, Negrin RS, et al High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1991;89:801–813.
   Google Scholar
• Chopra R, McMillan AK, Linch DC, et al The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single center 8-year study of 155 patients. Blood 1993;81:1137–1145.
   PubMed Web of Science ®Google Scholar
• Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage chemotherapy and high-dose therapy with autografting for recurrent and refractory Hodgkin's disease. Blood 1997;89:814–822.
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, et al Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395–1404.
   PubMed Web of Science ®Google Scholar
• Forrest DL, Hogge DE, Nevill TJ, et al High-dose therapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasm for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 2005;23:7994–8002.
   PubMed Web of Science ®Google Scholar
• Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol 2008;26:5240–5247.
   PubMed Web of Science ®Google Scholar